The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.